Assessment of Steatosis and Fibrosis in Liver Transplant Recipients Using Controlled Attenuation Parameter and Liver Stiffness Measurements

Table 8

Univariate and multivariate analysis of predictors of advanced fibrosis.

Variables	Univariate		Multivariate
	OR (95% CI)	value	OR (95% CI)	value
Age at LT, years	0.98 (0.95–1.01)	0.146
Age at TE, years	0.98 (0.95–1.02)	0.309
Donor age, years	1.01 (0.98–1.02)	0.580
Gender (female ref.)	1.21 (0.56–2.59)	0.627
Cause of liver disease, % (n)
Autoimmune liver disease	0.53 (0.15–1.92)	0.337
Alcoholic liver disease	1.62 (0.79–3.31)	0.191
HCV	1.64 (0.29–9.27)	0.577
Others	0.77 (0.39–1.55)	0.465
BMI, kg/m^2 (IQR)	1.03 (0.93–1.14)	0.541
Donors BMI, kg/m^2 (IQR)	1.05 (0.95–1.15)	0.342
Hypertension, % (n)	2.00 (0.91–4.42)	0.085
Diabetes, % (n)	1.40 (0.70–2.83)	0.342
Thrombocytes	0.99 (0.98–1.01)	0.468
Glucose, mmol/L (IQR)	1.13 (0.99–1.28)	0.067
Total bilirubin, mg/dL (IQR)	1.03 (1.01–1.07)	0.046	1.01 (0.95–1.06)	0.962
ALT, U/L (IQR)	1.02 (1.01–1.03)	0.002	0.98 (0.96–1.01)	0.360
AST, U/L (IQR)	1.04 (1.02–1.05)	<0.001	1.03 (0.99–1.07)	0.064
GGT, U/L (IQR)	1.02 (1.01–1.04)	<0.001	1.04 (1.01–1.06)	0.031
Triglyceride, mmol/L (IQR)	1.46 (1.02–2.11)	0.047
Total cholesterol, mmol/L (IQR)	0.78 (0.56–1.06)	0.150
LDL, mmol/L (IQR)	1.35 (1.02–.1.65)	0.040	1.30 (0.90–1.64)	0.126
HDL, mmol/L (IQR)	0.91 (0.36–2.30)	0.837
CRP, mg/L (IQR)	0.99 (0.95–1.03)	0.640
CAP, db/m	1.00 (0.99–1.02)	0.491
Time from LT to TE, years (IQR)	1.13 (0.99–1.27)	0.053

LT, liver transplantation; NAFLD, nonalcoholic fatty liver disease; HCV, hepatitis C virus infection; BMI, body mass index; AST, serum aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gamma-glutamyl transferase; CRP, C-reactive protein; CAP, controlled attenuation parameter; TE, transient elastography.